bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Authors: Ma Yuanqing , Joyce Allison , Brandenburg Olivia , Saatchi Faeze , Stevens Christina , Toffessi Tcheuyap Vanina , Christie Alana , Do Quyen N. , Fatunde Oluwatomilade , Macchiaroli Alyssa , Wong So C. , Woolford Layton , Yousuf Qurratulain , Miyata Jeffrey , Carrillo Deyssy , Onabolu Oreoluwa , McKenzie Tiffani , Mishra Akhilesh , Hardy Tanner , He Wei , Li Daniel , Ivanishev Alexander , Zhang Qing , Pedrosa Ivan , Kapur Payal , Schluep Thomas , Kanner Steven B. , Hamilton James , Brugarolas James
Published: April 2023

Figure S1
Supplementary Table 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
Authors: Haertle Larissa , Barrio Santiago , Munawar Umair , Han Seungbin , Zhou Xiang , Simicek Michal , Vogt Cornelia , Truger Marietta , Fernandez Rafael Alonso , Steinhardt Maximilian , Weingart Julia , Snaurova Renata , Nerreter Silvia , Teufel Eva , Garitano-Trojaola Andoni , Da Viá Matteo , Ruiz-Heredia Yanira , Rosenwald Andreas , Bolli Niccolò , Hajek Roman , Raab Peter , Raab Marc S. , Weinhold Niels , Haferlach Claudia , Haaf Thomas , Martinez-Lopez Joaquin , Einsele Hermann , Rasche Leo , Kortüm K. Martin
Published: April 2023

Raw data measurements of the dual-luciferase reporter assay in the L363 cell line. All measurements were performed in duplicates on 20.000 cells.
Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Authors: Cillo Anthony R. , Mukherjee Elina , Bailey Nathanael G. , Onkar Sayali , Daley Jessica , Salgado Claudia , Li Xiang , Liu Dongyan , Ranganathan Sarangarajan , Burgess Melissa , Sembrat John , Weiss Kurt , Watters Rebecca , Bruno Tullia C. , Vignali Dario A.A. , Bailey Kelly M.
Published: April 2023

Supplementary Table from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Supplementary Figure 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
Authors: Haertle Larissa , Barrio Santiago , Munawar Umair , Han Seungbin , Zhou Xiang , Simicek Michal , Vogt Cornelia , Truger Marietta , Fernandez Rafael Alonso , Steinhardt Maximilian , Weingart Julia , Snaurova Renata , Nerreter Silvia , Teufel Eva , Garitano-Trojaola Andoni , Da Viá Matteo , Ruiz-Heredia Yanira , Rosenwald Andreas , Bolli Niccolò , Hajek Roman , Raab Peter , Raab Marc S. , Weinhold Niels , Haferlach Claudia , Haaf Thomas , Martinez-Lopez Joaquin , Einsele Hermann , Rasche Leo , Kortüm K. Martin
Published: April 2023

Cell survival of DNMTi pretreated KMS11 cells under BTZ exposure.
AlamarBlue assay after 72 hours of incubation with varying concentrations of BTZ (0.5 nM to 4 nM) on DNMTi pretreated cells (48 h 500 nM Aza, 72 h 100 nM Dec) and PI naïve KMS11. No resensitizing effect to PI treatment was observed.
Supplementary Data from Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors
Authors: Solomon James P. , Yang Soo-Ryum , Choudhury Noura J. , Ptashkin Ryan N. , Eslamdoost Nasrin , Falcon Christina J. , Martin Axel , Plodkowski Andrew , Wilhelm Clare , Shen Ronglai , Ladanyi Marc , Berger Michael , Zhang Yanming , Drilon Alexander , Arcila Maria E.
Published: April 2023

Supplementary Data from Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors
Supplementary Figure from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Authors: Cillo Anthony R. , Mukherjee Elina , Bailey Nathanael G. , Onkar Sayali , Daley Jessica , Salgado Claudia , Li Xiang , Liu Dongyan , Ranganathan Sarangarajan , Burgess Melissa , Sembrat John , Weiss Kurt , Watters Rebecca , Bruno Tullia C. , Vignali Dario A.A. , Bailey Kelly M.
Published: April 2023

Supplementary Figure from Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Supplementary Table from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Authors: Lim Emerson A. , Bendell Johanna C. , Falchook Gerald S. , Bauer Todd M. , Drake Charles G. , Choe Jennifer H. , George Daniel J. , Karlix Janet L. , Ulahannan Susanna , Sachsenmeier Kris F. , Russell Deanna L. , Moorthy Ganesh , Sidders Ben S. , Pilling Elizabeth A. , Chen Huifang , Hattersley Maureen M. , Das Mayukh , Kumar Rakesh , Pouliot Gayle P. , Patel Manish R.
Published: April 2023

Supplementary Table from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Supplementary Figures FS1 from Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer
Authors: Dias Costa Andressa , Väyrynen Sara A. , Chawla Akhil , Zhang Jinming , Väyrynen Juha P. , Lau Mai Chan , Williams Hannah L. , Yuan Chen , Morales-Oyarvide Vicente , Elganainy Dalia , Singh Harshabad , Cleary James M. , Perez Kimberly , Ng Kimmie , Freed-Pastor William , Mancias Joseph D. , Dougan Stephanie K. , Wang Jiping , Rubinson Douglas A. , Dunne Richard F. , Kozak Margaret M. , Brais Lauren , Reilly Emma , Clancy Thomas , Linehan David C. , Chang Daniel T. , Hezel Aram F. , Koong Albert C. , Aguirre Andrew J. , Wolpin Brian M. , Nowak Jonathan A.
Published: April 2023

Supplementary Figures
Supplementary Table S2 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Authors: O'Connell Casey L. , Baer Maria R. , Ørskov Andreas Due , Saini Sunil Kumar , Duong Vu H. , Kropf Patricia , Hansen Jakob Werner , Tsao-Wei Denice , Jang Hyo Sik , Emadi Ashkan , Holmberg-Thyden Staffan , Cowland Jack , Brinker Brett T. , Horwood Kristin , Burgos Ryan , Hostetter Galen , Youngblood Benjamin A. , Hadrup Sine Reker , Issa Jean-Pierre , Jones Peter , Baylin Stephen B. , Siddiqi Imran , Grønbaek Kirsten
Published: April 2023

Grade 3 or Higher Toxicities or Toxicities Observed in 10% or More Patients – Excluding Those Defined as Unrelated or Unlikely Related to Protocol Treatment.
Supplementary Figure S4 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Authors: Mishra Akhilesh , Kumar Dhiraj , Gupta Kuldeep , Lofland Gabriela , Sharma Ajay Kumar , Banka Dhanush S. , Hobbs Robert F. , Dannals Robert F. , Rowe Steven P. , Gabrielson Edward , Nimmagadda Sridhar
Published: April 2023

Evaluation of [68Ga]Ga-DK223 in genetically hPD-L1 overexpressing model.
Supplementary Methods from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Authors: O'Connell Casey L. , Baer Maria R. , Ørskov Andreas Due , Saini Sunil Kumar , Duong Vu H. , Kropf Patricia , Hansen Jakob Werner , Tsao-Wei Denice , Jang Hyo Sik , Emadi Ashkan , Holmberg-Thyden Staffan , Cowland Jack , Brinker Brett T. , Horwood Kristin , Burgos Ryan , Hostetter Galen , Youngblood Benjamin A. , Hadrup Sine Reker , Issa Jean-Pierre , Jones Peter , Baylin Stephen B. , Siddiqi Imran , Grønbaek Kirsten
Published: April 2023

Isolation and DNA extraction of bone marrow cell populations; Targeted DNA sequencing; Peripheral blood mononuclear cell (PBMC) staining and flow cytometry analysis
Supplementary Figure S3 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Authors: O'Connell Casey L. , Baer Maria R. , Ørskov Andreas Due , Saini Sunil Kumar , Duong Vu H. , Kropf Patricia , Hansen Jakob Werner , Tsao-Wei Denice , Jang Hyo Sik , Emadi Ashkan , Holmberg-Thyden Staffan , Cowland Jack , Brinker Brett T. , Horwood Kristin , Burgos Ryan , Hostetter Galen , Youngblood Benjamin A. , Hadrup Sine Reker , Issa Jean-Pierre , Jones Peter , Baylin Stephen B. , Siddiqi Imran , Grønbaek Kirsten
Published: April 2023

A& B. Frequency (A) and intensity (B) of PD-1+ CD8+ T cells by gender) before (PRE), after second treatment cycle (C2D1 or C2D8; EARLY), and after third or fourth treatment cycle (C4D1, C4D8 or C5D1; LATE). CD8+ T cell expressing CD39 (C) and CD69 (D). F: females, M: males
Supplementary Table S3 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
Authors: Zhou Yan , Yang Qingcheng , Dong Yang , Ji Tong , Zhang Bing , Yang Cheng , Zheng Shuier , Tang Lina , Zhou Chenliang , Qian Guowei , Huang Yujing , Yu Wenxi , Li Hongtao , Wang Yonggang , He Aina , Shen Zan , Bao Qiyuan , Hua Yingqi , Bai Hongyu , Zhao Jiayi , Li Xiaoyi , Dai Xiangrong , Zhang Jianjun , Hu Haiyan , Yao Yang
Published: April 2023

Pharmacokinetic parameters after single dose administration
Supplementary Tables S1-S10 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2023

Table S1. Negative control samples used for LOB determination; Table S2. Quality of sequencing of BRAF and RAS genes; Table S3. REMARK checklist; Table S4. Patient characteristics; Table S5. Safety profiles; Table S6. Adverse event data; Table S7. Association of detectable ctDNA at baseline and patient characteristics; Table S8. Response in the LctDNA and HctDNA group; Table S9. BRAF V600E mutation analysis in patient 13; Table S10. Clinical trials comparing anti-EGFR and anti-VEGF in first-line therapy of RAS WT mCRC.
Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Authors: Robert Caroline , Lebbé Céleste , Lesimple Thierry , Lundström Eija , Nicolas Valérie , Gavillet Bruno , Crompton Philippa , Baroudjian Barouyr , Routier Emilie , Lejeune Ferdy J.
Published: April 2023

Immunohistology: Response at time of biopsy, tissue, date biopsies, previous CPI and protocol CPI, elapse times, TILs and macrophages phenotypes.
Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Authors: Robert Caroline , Lebbé Céleste , Lesimple Thierry , Lundström Eija , Nicolas Valérie , Gavillet Bruno , Crompton Philippa , Baroudjian Barouyr , Routier Emilie , Lejeune Ferdy J.
Published: April 2023

Previous therapies and outcome
Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Authors: Robert Caroline , Lebbé Céleste , Lesimple Thierry , Lundström Eija , Nicolas Valérie , Gavillet Bruno , Crompton Philippa , Baroudjian Barouyr , Routier Emilie , Lejeune Ferdy J.
Published: April 2023

Age, localisation primary, stage, TNM
Figure S4 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Authors: Debie Yana , Van Audenaerde Jonas R.M. , Vandamme Timon , Croes Lieselot , Teuwen Laure-Anne , Verbruggen Lise , Vanhoutte Greetje , Marcq Elly , Verheggen Lisa , Le Blon Debbie , Peeters Bart , Goossens Maria E. , Pannus Pieter , Ariën Kevin K. , Anguille Sébastien , Janssens Annelies , Prenen Hans , Smits Evelien L.J. , Vulsteke Christof , Lion Eva , Peeters Marc , van Dam Peter A.
Published: April 2023

Supplementary Figure 4: Spike-specific CD4+ T cell responses post homologous or heterologous booster vaccination in subcohorts.
Supplementary Table S3 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Authors: Cheema Amrita K. , Li Yaoxiang , Ventimiglia Mary , Kowalczyk Keith , Hankins Ryan , Bandi Gaurav , Janowski Einsley-Marie , Grindrod Scott , Villagra Alejandro , Dritschilo Anatoly
Published: April 2023

Validation of metabolite identification using tandem mass spectrometry-based fragmentation matching.
Supplementary Materials and Methods from Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Authors: Kinneer Krista , Wortmann Philipp , Cooper Zachary A. , Dickinson Niall J. , Masterson Luke , Cailleau Thais , Hutchinson Ian , Vijayakrishnan Balakumar , McFarlane Mary , Ball Kathryn , Davies Michael , Lewis Arthur , Huang Yue , Rosenbaum Anton I. , Yuan Jiaqi , Chesebrough Jon , Anderton Judith , Monks Noel , Novick Steven , Wang Jixin , Dimasi Nazzareno , Christie R. James , Sabol Darrin , Tosto Frances Anne , Wallez Yann , Leo Elisabetta , Albertella Mark R. , Staniszewska Anna D. , Tice David A. , Howard Philip W. , Luheshi Nadia , Sapra Puja
Published: April 2023

Surface plasmon resonance; In vitro cytotoxicity assays; In vitro proliferation assays; Internalization assays; Subcellular localization microscopy; Immunoblotting; Statistical analysis
Figure S2 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Authors: Pietrantonio Filippo , Manca Paolo , Bellomo Sara Erika , Corso Simona , Raimondi Alessandra , Berrino Enrico , Morano Federica , Migliore Cristina , Niger Monica , Castagnoli Lorenzo , Pupa Serenella Maria , Marchiò Caterina , Di Bartolomeo Maria , Restuccia Eleonora , Lambertini Chiara , Tabernero Josep , Giordano Silvia
Published: April 2023

PFS (A) and OS (B) in the biomarker evaluable population according to the randomly allocated treatment arm.
Supplementary Figures S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
Authors: van 't Erve Iris , Medina Jamie E. , Leal Alessandro , Papp Eniko , Phallen Jillian , Adleff Vilmos , Chiao Elaine Jiayuee , Arun Adith S. , Bolhuis Karen , Simmons John K. , Karandikar Aanavi , Valkenburg Kenneth C. , Sausen Mark , Angiuoli Samuel V. , Scharpf Robert B. , Punt Cornelis J.A. , Meijer Gerrit A. , Velculescu Victor E. , Fijneman Remond J.A.
Published: April 2023

The Supplementary Figures file consists of Supplementary Figures 1 to 15 belonging to the manuscript: "Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells"
Supplementary figure 3 from Characterization of Cell-Free DNA Size Distribution in Osteosarcoma Patients
Authors: Udomruk Sasimol , Phanphaisarn Areerak , Kanthawang Thanat , Sangphukieo Apiwat , Sutthitthasakul Songphon , Tongjai Siripong , Teeyakasem Pimpisa , Thongkumkoon Patcharawadee , Orrapin Santhasiri , Moonmuang Sutpirat , Klangjorhor Jeerawan , Pasena Arnat , Suksakit Pathacha , Dissook Sivamoke , Puranachot Pitithat , Settakorn Jongkolnee , Pusadee Tonapha , Pruksakorn Dumnoensun , Chaiyawat Parunya
Published: April 2023

Supplementary figure 3. The comparison of cfDNA fragment size distribution pattern between two techniques analysis; automated capillary electrophoresis and genome wide sequencing of sample (A) OS07 (B) OS08, and (C) OS10. For automated capillary electrophoresis, the distribution of cfDNA fragment was analyzed and presented as electropherogram by QIAxcel screengel software. While all read of insert size obtained from whole-genome sequencing was plotted as histogram using Picard software.
Supplementary figure 1 from Characterization of Cell-Free DNA Size Distribution in Osteosarcoma Patients
Authors: Udomruk Sasimol , Phanphaisarn Areerak , Kanthawang Thanat , Sangphukieo Apiwat , Sutthitthasakul Songphon , Tongjai Siripong , Teeyakasem Pimpisa , Thongkumkoon Patcharawadee , Orrapin Santhasiri , Moonmuang Sutpirat , Klangjorhor Jeerawan , Pasena Arnat , Suksakit Pathacha , Dissook Sivamoke , Puranachot Pitithat , Settakorn Jongkolnee , Pusadee Tonapha , Pruksakorn Dumnoensun , Chaiyawat Parunya
Published: April 2023

Supplementary figure 1. To identify peak of cfDNA fragments, (A) the scheme electropherograms illustrated the identification of cfDNA fragments using cutoff of ≤150 bp, samples with at least one detected cfDNA peak shorter than or equal to 150 bp are considered positive, whereas samples with all cfDNA peaks longer than 150 bp are considered negative. (B) The electropherograms represented the distribution of all detectable peak of cfDNA found in plasma samples from osteosarcoma patients. The table demonstrated the detectable sub-peaks and main peaks in each sample.
Supplementary Table S2 from Preoperative Neutrophil-to-Lymphocyte Ratio and a New Inflammatory Biomarkers Prognostic Index for Primary Retroperitoneal Sarcomas: Retrospective Monocentric Study
Authors: Fiore Marco , Ljevar Silva , Pasquali Sandro , Morelli Daniele , Callegaro Dario , Sanfilippo Roberta , Barisella Marta , Sangalli Claudia , Miceli Rosalba , Gronchi Alessandro
Published: April 2023

Supplemental Table 2. Prognostic Index of Inflammatory Biomarkers for primary Retroperitoneal Sarcoma (IBPI)
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Authors: Davis Andrew A. , Luo Jingqin , Zheng Tiantian , Dai Chao , Dong Xiaoxi , Tan Lu , Suresh Rama , Ademuyiwa Foluso O. , Rigden Caron , Rearden Timothy P. , Clifton Katherine , Weilbaecher Katherine , Frith Ashley , Tandra Pavan K. , Summa Tracy , Haas Brittney , Thomas Shana , Hernandez-Aya Leonel F. , Peterson Lindsay L. , Wang Xiaohong , Luo Shujun J. , Zhou Kemin , Du Pan , Jia Shidong , King Bonnie L. , Krishnamurthy Jairam , Ma Cynthia X.
Published: April 2023

Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.
Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.
Supplementary Figure S3. High correlation between bTMB determined from WES and a 152- gene targeted sequencing panel.
Supplementary Figure S4. Association between high cfDNA yield and shorter PFS.
Supplementary Figure S5. High baseline tumor fraction is associated with shorter PFS.
Supplementary Figure S6. bTMB scores are not associated with sites of metastatic spread.
Supplementary Figure S7. Specific oncogenic signaling pathways are more frequently altered in patients with high bTMB and bCNB scores.
Supplementary Figure S8. Genomic landscape of all patients at baseline.
Supplementary Figure S9. bTMB and bCNB at baseline vs. progression.
Supplementary Figure S10. Correlation between baseline bCNB and bTMB.
Supplementary Figure S11. Comparison of ctDNA dynamics as measured by ctDNA fraction and bCNB during treatment and progression.
Supplementary Figure S12. Genome-wide plots of copy number changes across treatment time points.
Supplementary Figure S13. Copy number changes detected for RB1 and BRCA2 genes across treatment time points.
Supplementary Figure S14. Relationship between ctDNA fraction and bTMB and bCNB
Supplementary Figure S15. Relationship between tumor fraction and bCNB.
Supplementary Table S3 from Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Authors: Bo Zhiyuan , Chen Bo , Zhao Zhengxiao , He Qikuan , Mao Yicheng , Yang Yunjun , Yao Fei , Yang Yi , Chen Ziyan , Yang Jinhuan , Yu Haitao , Ma Jun , Wu Lijun , Chen Kaiyu , Wang Luhui , Wang Mingxun , Shi Zhehao , Yao Xinfei , Dong Yulong , Shi Xintong , Shan Yunfeng , Yu Zhengping , Wang Yi , Chen Gang
Published: April 2023

Baseline characteristics between patients with unresectable HCC treated with lenvatinib in the training and external validation cohort.
Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Authors: Elía Andrés , Saldain Leo , Vanzulli Silvia I. , Helguero Luisa A. , Lamb Caroline A. , Fabris Victoria , Pataccini Gabriela , Martínez-Vazquez Paula , Burruchaga Javier , Caillet-Bois Ines , Spengler Eunice , Acosta Haab Gabriela , Liguori Marcos , Castets Alejandra , Lovisi Silvia , Abascal María F. , Novaro Virginia , Sánchez Jana , Muñoz Javier , Belizán José M. , Abba Martín C. , Gass Hugo , Rojas Paola , Lanari Claudia
Published: April 2023

Proteomics: DE and Reactome of Nuc proteins
Supplementary Figure S4 from Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Authors: Bo Zhiyuan , Chen Bo , Zhao Zhengxiao , He Qikuan , Mao Yicheng , Yang Yunjun , Yao Fei , Yang Yi , Chen Ziyan , Yang Jinhuan , Yu Haitao , Ma Jun , Wu Lijun , Chen Kaiyu , Wang Luhui , Wang Mingxun , Shi Zhehao , Yao Xinfei , Dong Yulong , Shi Xintong , Shan Yunfeng , Yu Zhengping , Wang Yi , Chen Gang
Published: April 2023

Clinical application of the machine learning radiomics models to predict the response to lenvatinib for unresectable HCC. Abbreviations: HCC, hepatocellular carcinoma; CECT, contrast enhanced computed tomography; ROI, region of interest.
Supplementary Figure S3 from Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Authors: Bo Zhiyuan , Chen Bo , Zhao Zhengxiao , He Qikuan , Mao Yicheng , Yang Yunjun , Yao Fei , Yang Yi , Chen Ziyan , Yang Jinhuan , Yu Haitao , Ma Jun , Wu Lijun , Chen Kaiyu , Wang Luhui , Wang Mingxun , Shi Zhehao , Yao Xinfei , Dong Yulong , Shi Xintong , Shan Yunfeng , Yu Zhengping , Wang Yi , Chen Gang
Published: April 2023

Principal component analysis of two radiomics-based subtypes predicting the response to lenvatinib for unresectable HCC. Abbreviations: HCC, hepatocellular carcinoma; PCA, principal component analysis.
Supplementary Table S2 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
Authors: Wilke Benjamin K. , Garner Hillary W. , Bestic Joseph M. , Chase Lori A. , Heckman Michael G. , Schoch Jennifer J. , Attia Steven
Published: April 2023

Comparison of SF-12 and VAS information between baseline, 6-month, and 24-month follow-up.
Supplementary Table S1 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
Authors: Wilke Benjamin K. , Garner Hillary W. , Bestic Joseph M. , Chase Lori A. , Heckman Michael G. , Schoch Jennifer J. , Attia Steven
Published: April 2023

Representativeness of Study Participants.
Supplementary Figure S5 from Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
Authors: Leto Simonetta M. , Ferri Martina , Sassi Francesco , Zanella Eugenia R. , Cottino Francesca , Vurchio Valentina , Catalano Irene , Ferrero Alessandro , Zingaretti Caterina C. , Marchiò Caterina , Grassi Elena , Trusolino Livio , Bertotti Andrea
Published: April 2023

Effect of BCL-XL inhibition on tumor growth in mCRC PDXs.
Supplementary Figure S2 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
Authors: Wilke Benjamin K. , Garner Hillary W. , Bestic Joseph M. , Chase Lori A. , Heckman Michael G. , Schoch Jennifer J. , Attia Steven
Published: April 2023

A Scatterplot demonstrating correlation between the early changes in post-contrast signal intensity and 24-month tumor volume.
Supplementary Data 1 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
Authors: Zhang Yi , Tacheva-Grigorova Silvia K. , Sutton Janette , Melton Zea , Mak Yvonne S.L. , Lay Cecilia , Smith Bryan A. , Sai Tao , Van Blarcom Thomas , Sasu Barbra J. , Panowski Siler H.
Published: April 2023

Supplementary Methods
Figure FS7 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
Authors: Zhang Yi , Tacheva-Grigorova Silvia K. , Sutton Janette , Melton Zea , Mak Yvonne S.L. , Lay Cecilia , Smith Bryan A. , Sai Tao , Van Blarcom Thomas , Sasu Barbra J. , Panowski Siler H.
Published: April 2023

Fig. S7. DLL3 CAR T cells demonstrate activity in intracranial tumor model without causing toxicity.
Figure FS6 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
Authors: Zhang Yi , Tacheva-Grigorova Silvia K. , Sutton Janette , Melton Zea , Mak Yvonne S.L. , Lay Cecilia , Smith Bryan A. , Sai Tao , Van Blarcom Thomas , Sasu Barbra J. , Panowski Siler H.
Published: April 2023

Fig. S6. Infusion of DLL3 CAR T cells did not induce toxicity in non-tumor-bearing model or subcutaneous tumor model.
Figure FS4 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
Authors: Zhang Yi , Tacheva-Grigorova Silvia K. , Sutton Janette , Melton Zea , Mak Yvonne S.L. , Lay Cecilia , Smith Bryan A. , Sai Tao , Van Blarcom Thomas , Sasu Barbra J. , Panowski Siler H.
Published: April 2023

Fig. S4. In vivo activity of DLL3 CAR T cells.
Figure FS2 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
Authors: Zhang Yi , Tacheva-Grigorova Silvia K. , Sutton Janette , Melton Zea , Mak Yvonne S.L. , Lay Cecilia , Smith Bryan A. , Sai Tao , Van Blarcom Thomas , Sasu Barbra J. , Panowski Siler H.
Published: April 2023

Fig. S2. DLL3 CAR T cells demonstrate specific cytotoxicity against DLL3-positive but not DLL3-negative targets.
Figure FS1 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
Authors: Zhang Yi , Tacheva-Grigorova Silvia K. , Sutton Janette , Melton Zea , Mak Yvonne S.L. , Lay Cecilia , Smith Bryan A. , Sai Tao , Van Blarcom Thomas , Sasu Barbra J. , Panowski Siler H.
Published: April 2023

Fig. S1 DLL3 is expressed in small cell lung tumors, PDX models and cell lines, with limited expression in normal tissue.
Supplementary Tables S1-S3 from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Authors: Aggarwal Charu , Saba Nabil F. , Algazi Alain , Sukari Ammar , Seiwert Tanguy Y. , Haigentz Missak , Porosnicu Mercedes , Bonomi Marcelo , Boyer Jean , Esser Mark T. , Cheng Lily I. , Agrawal Sonia , Jennings Emily C. , Durham Nicholas M. , Fraser Karl , Lissa Delphine , Gong Maozhen , Ceaicovscaia Natalia , Gascó Hernández Amaya , Kumar Rakesh
Published: April 2023

Supplementary Table S1. Representativeness of Study Participants
Supplementary Table S2. Disease response as assessed by RECIST v1.1 by PD-L1 tumor cell expression (response-evaluable population).
Supplementary Table S3. Disease response as assessed by RECIST v1.1 in prior line of therapy subgroups (response-evaluable population) and survival (as-treated population).
Supplementary Table S5: STING-based Clinical Trials from ENPP1 Immunobiology as a Therapeutic Target
Authors: Ruiz-Fernández de Córdoba Borja , Martínez-Monge Rafael , Lecanda Fernando
Published: April 2023

STING-based Clinical Trials
Supplementary Table S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Authors: Holtan Shernan G. , Savid-Frontera Constanza , Walton Kelly , Eaton Anne A. , Demorest Connor , Hoeschen Andrea , Zhang Ling , Reid Kayla , Kurian Tony , Sayegh Zena , Julia Estefania , Maakaron Joseph , Bachanova Veronika , Jurdi Najla El , MacMillan Margaret L. , Weisdorf Daniel J. , Felices Martin , Miller Jeffrey S. , Blazar Bruce R. , Davila Marco L. , Betts Brian C.
Published: April 2023

Key Reagents
Supplementary Table S2: Clinical trials of CD39 inhibitors from ENPP1 Immunobiology as a Therapeutic Target
Authors: Ruiz-Fernández de Córdoba Borja , Martínez-Monge Rafael , Lecanda Fernando
Published: April 2023

Clinical trials of CD39 inhibitors
Supplemental Table 4 from Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
Authors: Mascarella Marco A. , Olonisakin Tolani F. , Rumde Purva , Vendra Varun , Nance Melonie A. , Kim Seungwon , Kubik Mark W. , Sridharan Shaum S. , Ferris Robert L. , Fenton Moon J. , Clayburgh Daniel R. , Ohr James P. , Joyce Sonali C. , Sen Malabika , Herman James G. , Grandis Jennifer R. , Zandberg Dan P. , Duvvuri Umamaheswar
Published: April 2023

Representativeness of study participants
Supplementary Table S1 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Table 1. Representativeness of Study Participants
Supplementary Methods S1 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Methods
Supplementary Figure S1 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
Supplementary Table S4 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry
Authors: Mezghani Nadia , Yao Alexandria , Vasilyeva Daria , Kaplan Nicole , Shackelford Austin , Yoon Angela , Phillipone Elizabeth , Dubey Sunil , Schwartz Gary K. , Taylor Alison M. , Momen-Heravi Fatemeh
Published: April 2023

Differentially expressed genes by race
Supplementary Table S3 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry
Authors: Mezghani Nadia , Yao Alexandria , Vasilyeva Daria , Kaplan Nicole , Shackelford Austin , Yoon Angela , Phillipone Elizabeth , Dubey Sunil , Schwartz Gary K. , Taylor Alison M. , Momen-Heravi Fatemeh
Published: April 2023

Differentially methylated genes in HNC patients by race
Supplementary Figure S1 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry
Authors: Mezghani Nadia , Yao Alexandria , Vasilyeva Daria , Kaplan Nicole , Shackelford Austin , Yoon Angela , Phillipone Elizabeth , Dubey Sunil , Schwartz Gary K. , Taylor Alison M. , Momen-Heravi Fatemeh
Published: April 2023

Lymph node involvement and copy number alterations by race
Supplementary Figure S9 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Authors: Wils Leon J. , Poell Jos B. , Brink Arjen , Evren Ilkay , Brouns Elisabeth R. , de Visscher Jan G.A.M. , Bloemena Elisabeth , Brakenhoff Ruud H.
Published: April 2023

Overview of CNA’s found in a cohort of 312 OSCC samples obtained from the TCGA database. Frequency of gains (in blue) and losses (in red) for the entire cohort are shown on the y-axis. Chromosomes are shown on the x-axis. Top 5 most frequently affected chromosome regions are indicated by black arrows.
Supplementary Figure S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Authors: Pikkusaari Sanna , Tumiati Manuela , Virtanen Anni , Oikkonen Jaana , Li Yilin , Perez-Villatoro Fernando , Muranen Taru , Salko Matilda , Huhtinen Kaisa , Kanerva Anna , Koskela Heidi , Tapper Johanna , Koivisto-Korander Riitta , Joutsiniemi Titta , Haltia Ulla-Maija , Lassus Heini , Hautaniemi Sampsa , Färkkilä Anniina , Hynninen Johanna , Hietanen Sakari , Carpén Olli , Kauppi Liisa
Published: April 2023

Image analysis workflow in ImageJ.
Supplementary Table S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Authors: Aldoss Ibrahim , Khaled Samer K. , Wang Xiuli , Palmer Joycelynne , Wang Yan , Wagner Jamie R. , Clark Mary C. , Simpson Jennifer , Paul Jinny , Vyas Vibhuti , Chien Sheng-Hsuan , Stein Anthony , Pullarkat Vinod , Salhotra Amandeep , Al Malki Monzr M. , Aribi Ahmed , Sandhu Karamjeet , Thomas Sandra H. , Budde Lihua E. , Marcucci Guido , Brown Christine E. , Forman Stephen J.
Published: April 2023

Exploratory Analysis - Landmark at Day 28 Univariate Cox Proportional Hazards Models for Relapse-Free Survival
Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Authors: Aldoss Ibrahim , Khaled Samer K. , Wang Xiuli , Palmer Joycelynne , Wang Yan , Wagner Jamie R. , Clark Mary C. , Simpson Jennifer , Paul Jinny , Vyas Vibhuti , Chien Sheng-Hsuan , Stein Anthony , Pullarkat Vinod , Salhotra Amandeep , Al Malki Monzr M. , Aribi Ahmed , Sandhu Karamjeet , Thomas Sandra H. , Budde Lihua E. , Marcucci Guido , Brown Christine E. , Forman Stephen J.
Published: April 2023

CD19-CAR T cells in CSF
Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
Authors: Wijetunga N. Ari , Goglia Alexander G. , Weinhold Nils , Berger Michael F. , Cislo Michael , Higginson Daniel S. , Chabot Kiana , Osman Ahmed M. , Schaff Lauren , Pentsova Elena , Miller Alexandra M. , Powell Simon N. , Boire Adrienne , Yang Jonathan T.
Published: April 2023

CNS and systemic disease status for each patient
Supplementary Data Table 4 from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
Authors: Cranmer Lee D. , Lu Yao , Heise Rachel S. , Ballman Karla V. , Loggers Elizabeth T. , Pollack Seth M. , Wagner Michael J. , Reinke Denise K. , Schöffski Patrick , Tap William D.
Published: April 2023

Univariable Cox regression of progression-free survival.
Supplementary Data Table 1 from Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)
Authors: Cranmer Lee D. , Lu Yao , Heise Rachel S. , Ballman Karla V. , Loggers Elizabeth T. , Pollack Seth M. , Wagner Michael J. , Reinke Denise K. , Schöffski Patrick , Tap William D.
Published: April 2023

Univariable logistic regression of grade 3-5 hematologic adverse events.
Supplementary fig 1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
Authors: Wijetunga N. Ari , Goglia Alexander G. , Weinhold Nils , Berger Michael F. , Cislo Michael , Higginson Daniel S. , Chabot Kiana , Osman Ahmed M. , Schaff Lauren , Pentsova Elena , Miller Alexandra M. , Powell Simon N. , Boire Adrienne , Yang Jonathan T.
Published: April 2023

Supplement Figure 1. Survival analysis for cohort. Overall survival (median=9 months) for the whole cohort is shown with a 95% confidence interval (blue).
Supplementary Figure S2 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
Authors: Graeser Monika , Gluz Oleg , Biehl Claudia , Ulbrich-Gebauer Daniel , Christgen Matthias , Palatty Jenci , Kuemmel Sherko , Grischke Eva-Maria , Augustin Doris , Braun Michael , Potenberg Jochem , Wuerstlein Rachel , Krauss Katja , Schumacher Claudia , Forstbauer Helmut , Reimer Toralf , Stefek Andrea , Fischer Hans Holger , Pelz Enrico , zu Eulenburg Christine , Kates Ronald , Ni Hua , Kolberg-Liedtke Cornelia , Feuerhake Friedrich , Kreipe Hans Heinrich , Nitz Ulrike , Harbeck Nadia
Published: April 2023

Supplementary Figure 2 shows association between RNA signatures and ypT0/is ypN0
"Supplementary Table S6 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
Authors: Graeser Monika , Gluz Oleg , Biehl Claudia , Ulbrich-Gebauer Daniel , Christgen Matthias , Palatty Jenci , Kuemmel Sherko , Grischke Eva-Maria , Augustin Doris , Braun Michael , Potenberg Jochem , Wuerstlein Rachel , Krauss Katja , Schumacher Claudia , Forstbauer Helmut , Reimer Toralf , Stefek Andrea , Fischer Hans Holger , Pelz Enrico , zu Eulenburg Christine , Kates Ronald , Ni Hua , Kolberg-Liedtke Cornelia , Feuerhake Friedrich , Kreipe Hans Heinrich , Nitz Ulrike , Harbeck Nadia
Published: April 2023

Supplementary Table 6 shows multivariate logistic regression models for predicting pCR (ypT0/is ypN0)
Supplementary Figure 2 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Authors: Blandin Anne-Florence , Giglio Ross , Graham Maya Srikanth , Garcia Guadalupe , Malinowski Seth , Woods Jared K. , Ramkissoon Shakti , Ramkissoon Lori , Dubois Frank , Schoolcraft Kathleen , Tsai Jessica , Wang Dayle , Jones Robert , Vogelzang Jayne , Pelton Kristine , Becker Sarah , Watkinson Fiona , Sinai Claire , Cohen Elizabeth F. , Booker Matthew A. , Tolstorukov Michael Y. , Haemels Veerle , Goumnerova Liliana , Wright Karen , Kieran Mark , Fehnel Katie , Reardon David , Tauziede-Espariat Arnault , Lulla Rishi , Carcamo Benjamin , Chaleff Stanley , Charest Alain , De Smet Frederik , Ligon Azra H. , Dubuc Adrian , Pages Melanie , Varlet Pascale , Wen Patrick Y. , Alexander Brian M. , Chi Susan , Alexandrescu Sanda , Kittler Ralf , Bachoo Robert , Bandopadhayay Pratiti , Beroukhim Rameen , Ligon Keith L.
Published: April 2023

Supplementary Figure 2: T1 post-contrast axial and sagittal images of ALK-fused and non ALK-altered GBMs and ALK staining in ALK-fused congenital GBMs. A. Example images from patients with ALK aberrations (76, 89, 116, 197)B. In contrast to those without ALK aberrations (right columns). Contrast is gadolinium for those where applicable and show enhancement within both the tumor categories.C. Representative H&E and ALK IHCs of congenital GBM harboring an ALK fusion.
Supplementary Figure S2 from Loss of CDKN2A Cooperates with WWTR1(TAZ)–CAMTA1 Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
Authors: Seavey Caleb N. , Hallett Andrea , Li Shuo , Che Kepeng , Pobbati Ajaybabu V. , Ma Shuang , Burtscher Ashley , Kanai Ryan , Lamar John M. , Rubin Brian P.
Published: April 2023

Ki67 staining and single-cell RNA sequencing
Supplementary Data 3 from Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms
Authors: Gurska Lindsay M. , Okabe Rachel , Schurer Alexandra , Tong Meng Maxine , Soto Mark , Choi Daniel , Ames Kristina , Glushakow-Smith Shira , Montoya Allison , Tein Ellen , Miles Linde A. , Cheng Haiying , Hankey-Giblin Pamela , Levine Ross L. , Goel Swati , Halmos Balazs , Gritsman Kira
Published: April 2023

Table S3
Data from Trastuzumab: A Picky Partner?
Authors: McArthur Heather L. , Hudis Clifford A.
Published: April 2023

Abstract
Preclinical and clinical models of HER2-positive breast cancer show that human epidermal growth factor receptor 2 (HER2)-targeted therapy with trastuzumab adds significant benefits and modest risks to conventional cytotoxic therapies. Building on this advance will likely depend on elucidation of relevant signaling pathways and mechanisms of action for effective HER2-targeted therapies. (Clin Cancer Res 2009;15(20):6311–3)
Data from High-Resolution DNA Copy Number Profiling of Malignant Peripheral Nerve Sheath Tumors Using Targeted Microarray-Based Comparative Genomic Hybridization
Authors: Mantripragada Kiran K. , Spurlock Gillian , Kluwe Lan , Chuzhanova Nadia , Ferner Rosalie E. , Frayling Ian M. , Dumanski Jan P. , Guha Abhijit , Mautner Victor , Upadhyaya Meena
Published: April 2023

Abstract
Purpose: Neurofibromatosis type 1 (NF1) is an autosomal dominant condition that predisposes to benign and malignant tumors. The lifetime risk of a malignant peripheral nerve sheath tumor (MPNST) in NF1 is ∼10%. These tumors have a poor survival rate and their molecular basis remains unclear. We report the first comprehensive investigation of DNA copy number across multitude of genes in NF1 tumors using high-resolution array comparative genomic hybridization (CGH), with the aim to identify molecular signatures that delineate malignant from benign NF1 tumors.

Experimental Design: We constructed an exon-level resolution microarray encompassing 57 selected genes and profiled DNA from 35 MPNSTs, 16 plexiform, and 8 dermal neurofibromas. Bioinformatic analysis was done on array CGH data to identify concurrent aberrations in malignant tumors.

Results: The array CGH profiles of MPNSTs and neurofibromas were markedly different. A number of MPNST-specific alterations were identified, including amplifications of ITGB4, PDGFRA, MET, TP73, and HGF plus deletions in NF1, HMMR/RHAMM, MMP13, L1CAM2, p16INK4A/CDKN2A, and TP53. Copy number changes of HMMR/RHAMM, MMP13, p16INK4A/CDKN2A, and ITGB4 were observed in 46%, 43%, 39%, and 32%, respectively of the malignant tumors, implicating these genes in MPNST pathogenesis. Concomitant amplifications of HGF, MET, and PDGFRA genes were also revealed in MPNSTs, suggesting the putative role of p70S6K pathway in NF1 tumor progression.

Conclusions: This study highlights the potential of array CGH in identifying novel diagnostic markers for MPNSTs.
Data from Overexpression of Stromal Cell–Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas
Authors: Barbieri Federica , Bajetto Adriana , Stumm Ralf , Pattarozzi Alessandra , Porcile Carola , Zona Gianluigi , Dorcaratto Alessandra , Ravetti Jean-Louis , Minuto Francesco , Spaziante Renato , Schettini Gennaro , Ferone Diego , Florio Tullio
Published: April 2023

Abstract
Purpose: Hypothalamic or locally produced growth factors and cytokines control pituitary development, functioning, and cell division. We evaluated the expression of the chemokine stromal cell–derived factor 1 (SDF1) and its receptor CXCR4 in human pituitary adenomas and normal pituitary tissues and their role in cell proliferation.

Experimental Design: The expression of SDF1 and CXCR4 in 65 human pituitary adenomas and 4 human normal pituitaries was determined by reverse transcription-PCR, immunohistochemistry, and confocal immunofluorescence. The proliferative effect of SDF1 was evaluated in eight fibroblast-free human pituitary adenoma cell cultures.

Results: CXCR4 mRNA was expressed in 92% of growth hormone (GH)-secreting pituitary adenomas (GHoma) and 81% of nonfunctioning pituitary adenomas (NFPA), whereas SDF1 was identified in 63% and 78% of GHomas and NFPAs, respectively. Immunostaining for CXCR4 and SDF1 showed a strong homogenous labeling in all tumoral cells in both GHomas and NFPAs. In normal tissues, CXCR4 and SDF1 were expressed only in a subset of anterior pituitary cells, with a lower expression of SDF1 compared with its cognate receptor. CXCR4 and SDF1 were not confined to a specific cell population in the anterior pituitary but colocalized with discrete subpopulations of GH-, prolactin-, and adrenocorticorticotropic hormone–secreting cells. Conversely, most of the SDF1-containing cells expressed CXCR4. In six of eight pituitary adenoma primary cultures, SDF1 induced a statistically significant increase in DNA synthesis that was prevented by the treatment with the CXCR4 antagonist AMD3100 or somatostatin.

Conclusions: CXCR4 and SDF1 are overexpressed in human pituitary adenomas and CXCR4 activation may contribute to pituitary cell proliferation and, possibly, to adenoma development `in humans.
Data from Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study
Authors: Albertella Mark R. , Loadman Paul M. , Jones Philip H. , Phillips Roger M. , Rampling Roy , Burnet Neil , Alcock Chris , Anthoney Alan , Vjaters Egils , Dunk Chris R. , Harris Peter A. , Wong Alvin , Lalani Alshad S. , Twelves Chris J.
Published: April 2023

Abstract
Purpose: AQ4N is a novel bioreductive prodrug under clinical investigation. Preclinical evidence shows that AQ4N penetrates deeply within tumors and undergoes selective activation to form AQ4, a potent topoisomerase II inhibitor, in hypoxic regions of solid tumors. This proof-of-principle, phase I study evaluated the activation, hypoxic selectivity, and safety of AQ4N in patients with advanced solid tumors.

Experimental Design: Thirty-two patients with cancer (8 glioblastoma, 9 bladder, 8 head and neck, 6 breast, and 1 cervix) received a single 200 mg/m2 dose of AQ4N before elective surgery. AQ4 and AQ4N levels in 95 tissues (tumor, healthy tissue) were assessed by liquid chromatography-tandem mass spectrometry. Tissue sections were also analyzed for AQ4 fluorescence using confocal microscopy, and for expression of the hypoxia-regulated glucose transporter, Glut-1.

Results: Activated AQ4 was detected in all tumor samples with highest levels present in glioblastoma (mean 1.2 μg/g) and head and neck (mean 0.65 μg/g) tumors; 22 of 32 patients had tumor AQ4 concentrations ≥0.2 μg/g, levels previously shown to be active in preclinical studies. In 24 of 30 tumor samples, AQ4 was detected at higher concentrations than in adjacent normal tissue (tumor to normal ratio range 1.1-63.6); distant skin samples contained very low concentrations of AQ4 (mean 0.037 μg/g). Microscopic evaluation of tumor sections revealed that AQ4 colocalized within regions of Glut-1+ hypoxic cells.

Conclusions: AQ4N was activated selectively in hypoxic regions in human solid tumors. Intratumoral concentrations of AQ4 exceeded those required for activity in animal models and support the evaluation of AQ4N as a novel tumor-targeting agent in future clinical studies.